ストックスクリーナーアプリを入手
26.42
1.93%
-0.52
前日終値:
$26.94
開ける：
$26.63
24時間の取引高:
729.10K
Relative Volume:
1.19
時価総額：
$2.01B
収益：
-
当期純損益:
$-64.16M
株価収益率:
-20.80
EPS:
-1.2702
ネットキャッシュフロー:
$-69.06M
1週間 パフォーマンス:
-2.33%
1か月 パフォーマンス:
+7.22%
6か月 パフォーマンス:
-30.24%
1年 パフォーマンス:
-39.82%
1日の値動き範囲:
$25.84
$26.77
1週間の範囲:
$25.84
$28.75
52週間の値動き範囲:
$24.16
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
CGON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.42 | 2.01B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2024-06-28 | 開始されました | BofA Securities | Buy |
| 2024-02-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 開始されました | Goldman | Neutral |
| 2024-02-20 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-14 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cg Oncology Inc (CGON) 最新ニュース
CG Oncology Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
CG Oncology announces mixed shelf offering - MSN
CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing - Marketscreener.com
CG Oncology, Inc. SEC 10-K Report - TradingView
CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates - Marketscreener.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - The Manila Times
Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains CG Oncology buy with $75 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains CG Oncology buy with $75 target - Investing.com India
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts - Benzinga
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial - Marketscreener.com
Cretostimogene shows promise in bladder cancer study By Investing.com - Investing.com Australia
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Cretostimogene shows promise in bladder cancer study - Investing.com India
CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment - Nasdaq
Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability - StockTitan
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Decreases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CG Oncology (NASDAQ:CGON) Stock Price Up 7.3% – Time to Buy? - Defense World
11,853 Shares in CG Oncology, Inc. (NASDAQ:CGON) Purchased by Arizona State Retirement System - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cg Oncology Inc (CGON): A Sitting Duck With -181.74% Upside Potential - Stocks Register
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - The Manila Times
CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress - Nasdaq
Major Clinical Trial Results: CG Oncology Unveils New Bladder Cancer Treatment Data at European Congress - StockTitan
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Morgan Stanley - Defense World
3 Analysts Assess CG Oncology: What You Need To Know - Benzinga
Oncolytic Adenovirus Market Set to Grow Substantially Through 2032, DelveInsight Projects | CG Oncology, Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc. - Barchart
Oncolytic Adenovirus Market Set to Grow Substantially Through - openPR
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Cg Oncology Inc (CGON) is looking forward to a strong quarter - SETE News
CG Oncology stock hits 52-week low at $24.15 amid challenges - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Rhumbline Advisers - Defense World
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can CG Oncology's CEO Presentation Reveal New Bladder Cancer Treatment Progress? - StockTitan
CG Oncology Enters Oversold Territory (CGON) - Nasdaq
CG Oncology stock hits 52-week low at $25.71 amid challenges - Investing.com Canada
Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Critical Analysis: Novozymes A/S (OTCMKTS:NVZMY) vs. CG Oncology (NASDAQ:CGON) - Defense World
Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Valneva (NASDAQ:VALN) and CG Oncology (NASDAQ:CGON) Head-To-Head Review - Defense World
UroGen Plots Expansion, Brings In A New Asset - Citeline News & Insights
Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Analysts - Defense World
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Cg Oncology Inc (CGON) 財務データ
収益
当期純利益
現金流量
EPS
Cg Oncology Inc (CGON) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director |
Mar 17 '25 |
Sale |
28.00 |
1,000 |
28,000 |
0 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):